Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human α1 type IV collagen expressed in Sf9 cells

被引:21
作者
Boosani, Chandra Shekhar
Sudhakar, Akulapalli [1 ]
机构
[1] Boys Town Natl Res Hosp, Dept Genet, Cell Signaling & Angiogenesis Lab, Omaha, NE 68131 USA
[2] Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA
[3] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68182 USA
关键词
non-collagenous alpha 1 chain of type IV collagen; human umbilical vein endothelial cell; basic fibroblast growth factor; Autographa californica nuclear polyhedrosis virus; matrix metalloproteinase;
D O I
10.1016/j.pep.2006.03.007
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
alpha 1(IV)NC1, a cleavage fragment of the carboxy terminal non-collagenous human alpha 1. chain of type IV collagen, is derived from the extracellular matrix specifically by MMP-2. Recently we determined the in vitro and in vivo anti-angiogenic activity of alpha 1(IV)NC1 and presently, its role in cancer therapy is under evaluation. To characterize alpha 1(IV)NC1 as a potential candidate for drug development and to test its efficacy in animal models, an effective method to produce a purified active form of alpha 1(IV)NC1 is needed. In the present study, expression of alpha 1(IV)NC1 in Sf9 cells using baculovirus expression system was discussed, this method was found to be effective in the production of a functionally active soluble form of the recombinant protein. The purified protein showed its characteristic activities such as inhibiting cell proliferation, migration, and tube formation in endothelial cells. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 20 条
  • [1] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [2] EXPRESSION OF ALEUTIAN MINK DISEASE PARVOVIRUS PROTEINS IN A BACULOVIRUS VECTOR SYSTEM
    CHRISTENSEN, J
    STORGAARD, T
    BLOCH, B
    ALEXANDERSEN, S
    AASTED, B
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (01) : 229 - 238
  • [3] Colorado PC, 2000, CANCER RES, V60, P2520
  • [4] FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
  • [5] INGBER D, 1988, LAB INVEST, V59, P44
  • [6] Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
    Kamphaus, GD
    Colorado, PC
    Panka, DJ
    Hopfer, H
    Ramchandran, R
    Torre, A
    Maeshima, Y
    Mier, JW
    Sukhatme, VP
    Kalluri, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (02) : 1209 - 1215
  • [7] Cloning, high level expression of human paraoxonase-3 in Sf9 cells and pharmacological characterization of its product
    Lu, HQ
    Zhu, J
    Zang, YH
    Ze, YG
    Qin, JC
    [J]. BIOCHEMICAL PHARMACOLOGY, 2005, 70 (07) : 1019 - 1025
  • [8] Distinct antitumor properties of a type IV collagen domain derived from basement membrane
    Maeshima, Y
    Colorado, PC
    Torre, A
    Holthaus, KA
    Grunkemeyer, JA
    Ericksen, MB
    Hopfer, H
    Xiao, YW
    Stillman, IE
    Kalluri, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) : 21340 - 21348
  • [9] Tumstatin, an endothelial cell-specific inhibitor of protein synthesis
    Maeshima, Y
    Sudhakar, A
    Lively, JC
    Ueki, K
    Kharbanda, S
    Kahn, CR
    Sonenberg, N
    Hynes, RO
    Kalluri, R
    [J]. SCIENCE, 2002, 295 (5552) : 140 - 143
  • [10] BASEMENT-MEMBRANE BIOSYNTHESIS AS A TARGET FOR DEVELOPING INHIBITORS OF ANGIOGENESIS WITH ANTITUMOR PROPERTIES
    MARAGOUDAKIS, ME
    MISSIRLIS, E
    KARAKIULAKIS, GD
    SARMONICA, M
    BASTAKIS, M
    TSOPANOGLOU, N
    [J]. KIDNEY INTERNATIONAL, 1993, 43 (01) : 147 - 150